MiCas9 increases large size gene knock-in rates and reduces undesirable on-target and off-target indel edits

Linyuan Ma¹, Jinxue Ruan¹, Jun Song¹, Luan Wen¹, Dongshan Yang¹, Jiangyang Zhao², Xiaofeng Xia², Y. Eugene Chen¹✉, Jifeng Zhang¹✉ & Jie Xu¹✉

Gene editing nuclease represented by Cas9 efficiently generates DNA double strand breaks at the target locus, followed by repair through either the error-prone non-homologous end joining or the homology directed repair pathways. To improve Cas9’s homology directed repair capacity, here we report the development of miCas9 by fusing a minimal motif consisting of thirty-six amino acids to spCas9. MiCas9 binds RAD51 through this fusion motif and enriches RAD51 at the target locus. In comparison to spCas9, miCas9 enhances double-stranded DNA mediated large size gene knock-in rates, systematically reduces off-target insertion and deletion events, maintains or increases single-stranded oligodeoxynucleotides mediated precise gene editing rates, and effectively reduces on-target insertion and deletion rates in knock-in applications. Furthermore, we demonstrate that this fusion motif can work as a “plug and play” module, compatible and synergistic with other Cas9 variants. MiCas9 and the minimal fusion motif may find broad applications in gene editing research and therapeutics.
Gene editing nucleases (GENs) represented by CRISPR (clustered regularly interspaced short palindromic repeats) (CRISPR-associated protein 9) and others have become mainstream tools in biomedical research and offer promising therapeutic potentials. These GENs efficiently create double-strand breaks (DSBs) at the target locus in the genome. The majority of the DSBs are repaired by the non-homologous end joining (NHEJ) mechanisms leading to insertions and deletions (indels). Homology directed repair (HDR), which generally occurs at a significantly lower frequency than NHEJ, is exploited to achieve knock-in (KI).

The use of GENs such as *Streptococcus pyogenes* Cas9 (spCas9) along with single-stranded oligodeoxynucleotide (ssODN) templates has allowed high precise gene editing (ss-PGE) rates often along with single-stranded oligodeoxynucleotide (ssODN) expressing plasmid DNA (pDNA) and spCas9-expressing pDNA on-target and off-target indel events and improving ds-KI rates still low and needs to be improved. Homologous recombination (HR) pathway, albeit the ds-KI rate is stranded DNA (ds-DNA) mediated KI (ds-KI) through the exploited to achieve knock-in (KI).

Results

Construction of miCas9. One of the key events in the HR process is the deposition of RAD51 by BRCA2 to the resected single-stranded DNA (ssDNA) overhang at DSB to form RAD51/ssDNA nucleoprotein filaments, the ultimate molecular species that performs homology search and strand exchange underlying homologous recombination. Prior studies have elucidated that a motif consisting of 36 AA encoded by BRCA2 Exon 27 (Brex27) binds RAD51, and stabilizes the RAD51/ssDNA nucleoprotein filaments. Hence, we hypothesize that the fusion of Brex27 to spCas9 will lead to local enrichment of RAD51 as well as stabilization of the RAD51/ssDNA nucleoprotein filaments at the Cas9-induced on-target and off-target DSBs, which consequently may have beneficial effects on reducing undesirable on-target and off-target indel events and improving ds-KI rates (Fig. 1a). Based on this rationale, we constructed miCas9-expressing plasmid DNA (pDNA) and spCas9-expressing pDNA on the same backbone using the same codon optimizations (Fig. 1b, c, and Supplementary Fig. 1a, b). In order to use Cas9s in the ribonucleoprotein (RNP) form, we expressed and purified Cas9 proteins in *E. coli* (Supplementary Fig. 1c). SpCas9 and miCas9 RNPs possesses similar DSB generation capacity, evidenced by in vitro digestion assay results (Supplementary Fig. 1d).

MiCas9 increases KI rates in ds-KI applications. We first compared the efficiencies to knock in the green fluorescent protein (GFP) gene to a safe harbor locus AAVS1 in human cells between miCas9 and spCas9. The ds-DNA donor template (GFP-donor-1k-AAVS1, Supplementary Fig. 2a and Supplementary Table 1) consists of the promoterless GFP coding sequence (989 bp) flanked by left (804 bp) and right (837 bp) homology arms (HAS). The percentage of GFP-positive cells (%) determined by flow cytometry analysis was used as an indicator of KI rates, as previously reported.

When Cas9s were delivered in their plasmid DNA (pDNA) form to fibroblast cells along with targeting guide RNA (sg-AAVS1, Supplementary Table 1) and GFP-donor-1k-AAVS1 donors, the %GFP+ cells was 2.5-fold higher in the miCas9 group than in the spCas9 group (2.93% vs. 1.19%) (Fig. 2a). Similar levels of improvement were confirmed in other cell types including airway epithelial cells (AECS, 0.72–1.49%) and induced pluripotent stem cells (iPSCs, 0.54–1.16%) (Fig. 2a). The donor integration at this locus appeared to be precise in GFP+ fibroblast cells as there were no detectable non-precise integrations at either the left junction or the right junction, in both spCas9 and miCas9 groups (Supplementary Fig. 2b, c). Increasing the KI fragment size from 989 bp (1K) to 2469 bp (2K) and 3339 bp (3K) (GFP-donor-2k-AAVS1, GFP-donor-3k-AAVS1, Supplementary Table 1) while keeping the same HAS slightly decreased the overall %GFP+ cells, but the rates were consistently 2–3-fold higher in the miCas9 group than in the spCas9 group (Supplementary Fig. 2d).

We further demonstrate that such improvement holds true when Cas9s were used in their RNP form. Using gRNAs and donor templates (GFP-donor-1k-AAVS1) targeting the AAVS1 locus, miCas9 RNPs led to significantly higher percentage of GFP+ cells than spCas9 RNPs did in both fibroblast (14.16% vs. 9.63%) and Jurkat cells (30.33% vs. 10.03%) (Fig. 2a).

To confirm that the ds-KI rate improvement achieved by miCas9 over spCas9 is not locus specific, we conducted a similar set of experiments at another locus ROSA26 (ref. 33), using corresponding gRNA and ds-DNA donor template (Supplementary Table 1). Consistently, compared to spCas9, the use of miCas9 improved GFP KI rate by 2–3-folds in fibroblast cells (1.35–3.04%), AECS (0.55–1.16%) and iPSCs (0.60–1.53%) (Supplementary Fig. 3a) when used in the pDNA form. When used in the form of RNPs, miCas9 also led to higher GFP+ cells than spCas9 RNPs did in both fibroblast (16.02% vs. 12.91%) and Jurkat cells (15.00% vs. 7.24%) (Supplementary Fig. 3a).

These results show that miCas9 improves ds-KI rates at different loci in different human cell types by multiple folds.

MiCas9 reduces on-target indel rates in ds-KI applications. The design of miCas9 suggests that this modified GEN will not only improve HR-mediated ds-KI rates but will also reduce the on-target indel rates. We therefore proceeded to test this at multiple loci including AAVS1, ROSA26, ATF4, AHR, RAD21, and TGIF2. In addition to spCas9, two HDR-fusion Cas9s, Cas9-HE (HE) and Cas9-Geminin (GE) that have been shown to enhance ds-KI rates, were included in the comparison. Different
variants of Cas9 were delivered in their pDNA format along with gRNAs and GFP-expressing ds-DNA donors for each locus to fibroblast cells (Supplementary Table 1).

At the AAVS1 locus, comparable percentage of GFP + cells were observed in the miCas9, Cas9-HE, and Cas9-GE groups (2.63–2.98%), all significantly higher than those in the spCas9 group (1.56%) (Fig. 2b). The on-target indel rate, revealed by next-generation sequencing (deep-seq) analysis, was lowest in the miCas9 (5.79%) group, followed by Cas9-HE (12.17%), and highest in the spCas9 (18.63%) and Cas9-GE (19.91%) groups (Fig. 2c).

Similar results were observed in the other five loci (ROSA26, ATF4, AHR, RAD21, and TGIF2). MiCas9, Cas9-HE, and Cas9-GE all resulted in an improved GFP KI rate than spCas9 did, but the lowest on-target indel rates were always achieved by miCas9, which was up to 75% lower than that by spCas9 and those by Cas9-HE and Cas9-GE (Supplementary Fig. 3b–f).

These results demonstrate that for ds-KI applications, miCas9 is superior to spCas9 in safety and efficacy performances by dramatically reducing the on-target indel rates and at the same time enhancing the KI rates. Comparing to two other HDR-fusion Cas9 variants (i.e. Cas9-HE and Cas9-GE), miCas9 possess the unique capacity to reduce on-target indel rates.

MiCas9 reduces off-target indel rates. Next we evaluated miCas9’s capacity in reducing off-target indel rates. The AAVS1 and ROSA26 sgRNAs are not suitable for demonstrating this feature as their off-target rates by miCas9 or spCas9 are both low (Supplementary Fig. 4a, b). To better evaluate this, we examined several loci that are reportedly associated with substantial off-target rates by corresponding gRNAs, namely sg1-VEGFA and sg2-VEGFA targeting VEGFA, sg-FANCF2 targeting FANCF2, and sg-EMX1 targeting EMX1 (refs. 23,34) (Supplementary Table 2) in Ad293 cells. We used miCas9 and spCas9 in their pDNA form because pDNA-mediated gene editing is known to be of higher off-target risks than those achieved by Cas9 RNP6.

Deep-seq analysis reveals that compared to spCas9, miCas9 effectively reduced indel rates at all of the off-target loci examined (Fig. 3a, b and Supplementary 4c, d), including sg1-VEGFA-OT1 (34.70 to 3.30%), sg2-VEGFA-OT1 (3.9 to 0.34%), sg2-VEGFA-OT2 (13.4 to 1.9%), sg-EMX1-OT1 (46.7 to 31.1%), and sg-FANCF2-OT1 (25.1 to 4.3%). The on-target indels rates associated with these gRNAs are also lower in the miCas9 group than in the spCas9 group, similar to those observed in ds-KI application (Fig. 3a, b and Supplementary Fig. 4c, d). These results show that compared to spCas9, miCas9 dramatically reduced off-target indel events.
To strengthen this finding, we next evaluated the off-target indel rates at Guide-seq predicted loci for sg1-VEGFA and sg-FANCF2 in Ad293 cells (Fig. 3c, d). In addition to spCas9 and miCas9, we included Cas9-HE and Cas9-GE representing HDR-improving Cas9s, and HiFiCas9 and HypeCas9 representing specificity-improving Cas9s in the comparison. For sg1-VEGFA, we evaluated nine Guide-seq predicted off-target (OT1 to OT9, Supplementary Table 2) loci (Fig. 3c). MiCas9 led to much lower indel rates in all these OT loci than spCas9 did. The extent of off-target indel reduction was similar between miCas9 and specificity-improving Cas9s (i.e. HypeCas9 and HiFiCas9). Cas9-HE, consisting of the CtIP fusion motif, also reduced off-target indel rates in general when compared to spCas9, but to a less extent compared to those by specificity-improving Cas9s and miCas9. Interestingly, Cas9-GE, consisting of a cell-cycle-modulating motif, did not show much effect, with indel rates similar to those observed in the spCas9 group. For sg-FANCF2, we evaluated 10 Guide-seq predicted off-target (OT1–OT10, Supplementary Table 2) loci (Fig. 3d). Similar to the patterns revealed for sg1-VEGFA, miCas9 was as effective as HypeCas9 and HiFiCas9 in reducing off-target indel rates, whereas Cas9-HE had moderate effects and Cas9-Geminin had the least effect.

These results show that miCas9 effectively reduces undesirable off-target indel rates.

**Fig. 2 MiCas9 increases KI rates and reduces on-target indel rates in ds-KI applications.** 

(a) Percentage of GFP⁺ cells after GFP ds-KI to the AAVS1 locus in different cell types. b Percentage of GFP⁺ cells after GFP knock-in at the AAVS1 locus using different nuclease. AEC: airway epithelial cells, iPSCs: induced pluripotent stem cells, RNP: Cas9/gRNA ribonucleoprotein, Sp: spCas9, Mi: miCas9, HE: Cas9-HE, GE: Cas9-GE. #Reads: Average amplicon reads per sample. Three independent experiments were performed for each condition. Data are presented as mean ± standard error of means (SEM). Unpaired t-test (two tailed) was used to compare data using GraphPad Prism 8 software (GraphPad Software, Inc., San Diego, CA). Source data are available in the Source Data file.

**MiCas9 reduces on-target indel rates without compromising efficacy in ss-PGE applications.** We then examined the effects of miCas9 on ss-PGE applications. We anticipated that miCas9 is capable of reducing undesirable on-target indel rates, as we have observed in ds-KI applications. We also wanted to learn if miCas9 has any effects on the PGE rates when ssODN donors are used. MiCas9 and spCas9 were delivered in their RNP form to human iPSCs, along with corresponding gRNAs and ss-ODNs for generating point mutations at five different loci including EGFR, B2M, MYBPC3, NKX2.1, and SOD1 (Supplementary Table 3). Deep-seq was employed to analyze both PGE rates and on-target indel rates. The Noise/Signal (N/S) value was calculated as the indel/PGE rates at a given locus.

At all five loci, the PGE rates were similar between miCas9 groups and spCas9 groups (Fig. 4a and Supplementary Fig. 7a–d), eliminating the concern that miCas9 may adversely affect the efficacy of ss-PGE. At four (i.e. EGFR, B2M, MYBPC3, and NKX2.1) out of these five (80%) loci, the on-target indel rates were significantly reduced by miCas9 compared to spCas9 (Fig. 4a and Supplementary Fig. 7a–d). For example, at the EGFR locus (Fig. 4a), the on-target indel rate was reduced from 21.4% in the spCas9 group to 2.96% in the miCas9 group, representing an 86% reduction [calculated as (high value–low value)/high value × 100]. At the B2M PGE locus (Fig. 4b), the on-target indel rate was reduced to below the detection limit (80%) loci, the on-target indel rates were significantly reduced by miCas9 compared to spCas9 (Fig. 4a and Supplementary Fig. 7a–d).
threshold, representing a 100% reduction. At the other locus SOD1 (1 out of 5, 20%, Supplementary Fig. 7c), however, the on-target indel rates were similar between the spCas9- and miCas9-treated cells (13.47% vs. 14.09%), indicating that miCas9 reduces on-target indel rates without compromising efficiency in ss-PGE applications.

We also used miCas9 and spCas9 RNPs, along with gRNA and ssODN donors (Supplementary Table 3) to generate the CCR5 delta32 mutation (CCR5-del32) in hematopoietic stem cells (HSCs), which has been pursued to render HIV-1 resistance in patients36 (Supplementary Fig. 7d). Consistent with earlier findings, the on-target indel rates were considerably lower than those in the spCas9 group (Fig. 4c, d and Supplementary Fig. 7e, f), indicating that miCas9 may enhance PGE rates in a locus-dependent manner.

Again, miCas9 did not compromise the efficacy of ss-PGE at any of the four loci comparing to spCas9. In fact, at the HBB and CCR5-C101 loci, higher PGE rates were found in the miCas9 group than those in the spCas9 group (Fig. 4c, d and Supplementary Fig. 7e, f), indicating that miCas9 may enhance PGE rates in a locus-dependent manner.

Consistent with earlier findings, the on-target indel rates were significantly reduced by miCas9 at three (HBB, CCR5-C101, and PSEN1) out of four additional PGE loci including HBB, CFTR-G542, CCR5-C101, and PSEN1 using corresponding gRNAs and ss-ODNs (Supplementary Table 3).

Fig. 3 MiCas9 reduces off-target indel rates. a Off-target and on-target indel rates associated with sg1-VEGFA by spCas9 and miCas9 pDNAs. b Off-target and on-target indel rates associated with sg-FANCF2 by spCas9 and miCas9 pDNAs. c Indel rates at Guide-seq predicted potential off-target loci associated with sg1-VEGFA by pDNAs of different nucleases. d Indel rates at Guide-seq predicted potential off-target loci associated with sg-FANCF2 by pDNAs of different nucleases. Sp: spCas9, Mi: miCas9, Hy: hypaCas9, Hi: HiFiCas9, HE: Cas9-HE, GE: Cas9-GE, NC: negative control with non-specific gRNA. #Reads: Average amplicon reads per sample. BD: below detection, representing values <0.10%. Three independent experiments were performed for each condition. Data are presented as mean ± standard error of means (SEM) in a and b, and as heat map in c and d. Unpaired t-test (two tailed) was used to compare data using GraphPad Prism 8 software (GraphPad Software, Inc., San Diego, CA). Source data are available in the Source Data file.

**MiCas9 outperforms Cas9-HE and Cas9-GE in ss-PGE applications.** Because miCas9 contains an HDR-enhancing motif Brex27, we next compared it with two representing HDR-fusion Cas9s, Cas9-HE, and Cas9-GE, at four additional PGE loci including HBB, CFTR-G542, CCR5-C101, and PSEN1 using corresponding gRNAs and ss-ODNs (Supplementary Table 3).

Because miCas9 contains an HDR-enhancing motif Brex27, we next compared it with two representing HDR-fusion Cas9s, Cas9-HE, and Cas9-GE, at four additional PGE loci including HBB, CFTR-G542, CCR5-C101, and PSEN1 using corresponding gRNAs and ss-ODNs (Supplementary Table 3).
Interestingly, the effects of Cas9-HE and Cas9-GE on ss-PGE applications appear different from theirs on ds-KI applications where both GENs enhanced ds-KI rates but had no effects in reducing on-target indels. At these ss-PGE loci, Cas9-HE lowered on-target indel rates consistently; however, at the cost of reduced PGE rates (Fig. 4c, d and Supplementary Fig. 7e, f). Cas9-GE also appeared capable of reducing on-target indels, but with an inconsistent PGE outcome. For example, at the PSEN1 locus (Supplementary Fig. 7i), Cas9-GE achieved similar PGE rates, on-target indel rates, and hence an N/S ratio like those by miCas9. However, at the HBB locus (Fig. 4c), Cas9-GE led to significantly lower PGE rates when comparing to all other three (i.e. spCas9, miCas9, and Cas9-HE). These results show that Cas9-HE and Cas9-GE, unlike miCas9, are associated with compromised PGE rates in ss-PGE applications.

Together, these data demonstrate that miCas9 universally maintains and sometimes enhances PGE rates, and is capable to reduce on-target indel rates at most loci in ss-PGE applications.

**Brex27 is a plug and play module that is compatible with other Cas9 variants.** Because the Brex27 consists of only 36 AA, we reasoned that this mini motif can be used as a “plug and play” module when fusing to other variants of GENs without introducing substantial size increase. We tested this strategy in the two examples below.

First, we constructed miHiFiCas9 (Fig. 5a) by fusing Brex27 to HiFiCas9 to see if additional reduction of off-target indel rates can be achieved. Indeed, miHiFiCas9 is shown to reduce the off-target indel rates of sg-FANCF2 (Supplementary Table 2) caused by spCas9 (26.53%), HiFiCas9 (13.13%) or miCas9 (8.18%) to a lower level (3.06%) (Fig. 5b), in which all Cas9 variants were delivered as pDNAs to Ad293 cells. This is an additional 76.7% reduction from that by HiFiCas9 or 62.6% reduction from that by miCas9, indicating a synergistic effect of the miCas9 and HiFiCas9 designs.

In another effort, we constructed miCas9mSA (Fig. 5a) by incorporating Brex27 to spCas9mSA, which was reported to increase large size gene KI rates by enriching Biotin-labeled donor templates at DSB sites, to investigate if this nuclease would further increase KI rates. We compared the success rates of knocking in the biotin-labeled ds-KI GFP construct (GFP-donor-1k-ROSA, Supplementary Table 1) to the ROSA26 locus in fibroblast cells using sg-ROSA (Supplementary Table 1), and Cas9s in their pDNA form. Flow cytometry results show that the highest percentage of GFP+ cells is achieved by miCas9mSA (5.50%), followed by spCas9mSA (4.31%), miCas9 (2.73%), and the lowest in spCas9 (1.45%) (Fig. 5c). These results demonstrate the additive beneficial effects of the Brex27 motif to spCas9mSA.

Together these results demonstrate that Brex27 can be used as a plug and play module that is compatible with other Cas9 variants.

**The improvement of miCas9 is Brex27 and RAD51 dependent.** Based on the design, miCas9 binds RAD51 through the Brex27 mini motif. To confirm this, we first constructed a mutant miCas9 (miCas9-mut) where a point mutation is introduced to the Brex27 coding sequence leading to a mutant peptide (Supplementary Fig. 8). As expected miCas9-mut lost the capacity to reduce on-target or off-target indel rates (Fig. 6a). On the other hand, the use of a RAD51 small-molecule inhibitor B02 (ref. 37) also eliminated the indel reduction capacity of miCas9 (Fig. 6b). These results show that both Brex27 and RAD51 are required for miCas9’s beneficial effects.

To prove that miCas9 binds to RAD51 directly, we performed co-immunoprecipitation (co-IP) in Ad293 cells treated with sg-AAVS1, GFP-donor-1k-AAVS1 donor templates (Supplementary Table 1) along with spCas9 or miCas9 pDNAs. Cas9s were pulled down by the anti-Flag antibodies followed by blotting with anti-RAD51 antibody. As shown in Fig. 6c, left panel, there are significantly higher levels of RAD51 signal detected in the miCas9 group than in the spCas9 group. In another set of experiment, the
co-IP was performed by anti-RAD51 antibody followed by blotting with anti-Cas9 antibody (Fig. 6c, right panel). Again, high level signals were detected in the miCas9 group where only background signals were detected in the spCas9 group. These results demonstrate that miCas9 directly binds to RAD51.

We then conducted the chromatin immunoprecipitation (ChIP) assay to assess if RAD51 were recruited and enriched by miCas9 at the target locus, also in Ad293 cells treated with sg-AAVS1, GFP-donor-1k-AAVS1 donor templates (Supplementary Table 1). As shown in Fig. 6d, miCas9 significantly enhanced the recruitment of RAD51 to the proximal region of the targeted locus than spCas9 did.

These results confirm that miCas9 relies on Brex27 for binding with RAD51 to achieve the beneficial effects.

Discussion

In the present work, we show that fusing a minimal motif Brex27 to spCas9 renders the variant miCas9 several desirable features: (i) improving ds-KI rates by multiple folds; (ii) reducing off-target indel events; (iii) maintaining or increasing ss-PGE rates; and (iv) reducing on-target indel rates in both ds-KI and ss-PGE applications. These benefits are consistent with the designing rationale that Brex27 reportedly binds to RAD51 and plays key roles in stabilizing the RAD51/ssDNA nucleoprotein filaments, and are corroborated by a recent report in which a Rad51-Cas9 nickase fusion protein mediated HDR while minimizing indels.

Adding Brex27 (36 AA) to spCas9 (1368 AA) increases its size by 2.6%. In contrast, other HDR-fusion motifs such as Geminin/GE (110 AA), CtIP/HE (296 AA), mSA (171 AA), DN1S (414 AA), and RAD52 (471 AA) are 306 to 1308% the size of Brex27. Despite its small size, Brex27 has significant HDR-enhancing capacity, leading to ds-KI rates that are 2–3 folds those by spCas9, similarly to those achieved by Cas9-HE and -GE.

The mini size of Brex27 may prove advantageous especially for in vivo gene editing therapy. Currently, adeno-associated virus (AAV) is the only viral vehicle approved by the U.S. Food and Drug Administration (FDA) for gene therapy, which has a packaging capacity of 4.7 kb, which is barely sufficient for packaging spCas9 (4.1 kb). Therefore, any substantial size increase in a Cas9 fusion protein variant will likely affects its eligibility for AAV-mediated delivery, whereas any “size-saving” on the Cas9 part means more packaging space for other elements. In this regard, miCas9 represents a promising variant for AAV-mediated gene editing therapy.

Importantly, at Guide-seq predicted loci for sg-VEGFA and sg-FANCF2, the mini size Brex27, but not the fusion motifs used in Cas9-HE and Cas9-GE, led to the highest reduction of the off-target indel rates (Fig. 3c, d and Supplementary Figs. 5 and 6) to a level comparable or even lower than those by other specificity-improving Cas9s such as HiFiCas9 and HypaCas9 (Fig. 3c, d). MiCas9 likely shares Guide-seq predicted off-target loci with those by spCas9 because no mutations are made in the Cas9 protein and no sequence or structural changes are made to the sgRNAs. However, there is the remote possibility that Cas9 variants such as miCas9 may induce their own characteristic sets of off-target loci. Follow-up studies may be needed to evaluate this, especially in any clinical-oriented applications.

It should be noted that miCas9 and specificity-improving Cas9s reduce off-target indel events through different mechanisms. MiCas9 works by increasing HDR after DSB generation, whereas specificity-improving Cas9s work by reducing non-specific cuts at the off-target sites. Hence it is conceivable that the
miCas9 strategy is compatible and may be synergistic with that of specificity-improving Cas9s. Indeed, as demonstrated in the present work, miHiFiCas9 was shown to further reduce off-target indel rates up to 77% over HiFiCas9 or up to 63% over miCas9, indicating an apparent synergistic effect by increased specificity and enhanced HDR.

One unique advantage of miCas9 is its capacity to reduce on-target indel rates in both ds-KI and ss-PGE applications, which does not come at the cost of reduced efficacy evidenced by improved ds-KI rates and uncompromised ss-PGE rates in the present study. On-target indel damage is a potential concern of gene editing although many studies have neglected attention to this genotoxic effect, which in clinical settings, should be at the forefront. It is important not to introduce new on-target indel mutations when trying to correct disease-causing mutations, for example on autosomal-dominant mutations or on tumor-associated genes. In comparison with spCas9, miCas9 universally reduces on-target indel rates by 52–75%, in all ds-KI loci (n = 6) examined. The reductions are 52–74% and 63–72%, comparing to Cas9-HE and Cas9-GE, respectively.

In ss-PGE applications, miCas9 was effective in reducing on-target indels, as much as 100%, on most of the loci (8 out of 10, 80%) examined, although we did notice exceptions (2 out of 10, 20%) where the on-target indel rates were similar between miCas9 and spCas9. This may indicate that at these two loci (e.g. SOD1 and CFTFR-G542) a RAD51-dependent mechanism (e.g. SSA) dominates the repair. Nevertheless, to our knowledge, miCas9 represents the smallest and only HDR-improving spCas9 strategy. Indeed, as demonstrated in the present study. On-target indel damage is a potential concern of gene editing although many studies have neglected attention to this genotoxic effect, which in clinical settings, should be at the forefront. It is important not to introduce new on-target indel mutations when trying to correct disease-causing mutations, for example on autosomal-dominant mutations or on tumor-associated genes. In comparison with spCas9, miCas9 universally reduces on-target indel rates by 52–75%, in all ds-KI loci (n = 6) examined. The reductions are 52–74% and 63–72%, comparing to Cas9-HE and Cas9-GE, respectively.

As demonstrated in the present work, we expect that miCas9 brings benefits to ds-KI and most ss-PGE applications. It is not suitable however if the purpose is to create gene knockout as a result of indel-caused premature stop codon. MiCas9 is expected to work synergistically with gRNA-based improving strategies, for example, the RNA aptamer–streptavidin strategy. The use of Brex27 can go beyond spCas9, as long as the fusion partner works in a RAD51-dependent manner, which would include most DSB-generating GENs, for example, the Staphylococcus aureus Cas9 (saCas9), for which extensive engineering and evolution work has yet to be conducted.

In summary, we show that a rationally designed HDR-fusion Cas9 variant miCas9 possess a unique combination of desirable features including improving ds-KI rates, reducing undesirable off-target events, and reducing on-target indel events in ds-KI and ss-PGE applications, providing a “one small stone for three birds” tool in gene editing. The mini size of Brex27 allows it to work as a plug and play module that will benefit many other GEN variants. MiCas9 and the Brex27 module may find broad applications in gene editing research and therapeutics.

**Methods**

**Cells.** Human fibroblast cells (Cat# CRL2522) were acquired from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured with RPMI-1640 Medium (Cat# 11875119; ThermoFisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS; Cat# FBS1824-001, Nucleus Biologics, San Diego, CA).

Human AECs were obtained from ATCC (Cat# PCS-300-010) and cultured with Airway Epithelial Cell Basal Medium (Cat# PCS-300-030, ATCC) supplemented with Bronchial Epithelial Cell Growth Kit (Cat# PCS-300-040, ATCC).

Human iPSC cells (Cat# ACS-1030, ATCC) were cultured in feeder-free condition in mTeSR1 (Cat# 85850, StemCell Technologies, Vancouver, Canada) on Matrigel (Cat# 354277, Corning Inc, Corning, NY)-coated cultureware surface.

---

**Fig. 6 MiCas9’s beneficial effects are Brex27 and RAD51 dependent. a** Indel rates by spCas9, miCas9, and miCas9-mutant on the on-target site for sg-AAVS1 and the off-target site 1 for sg-EMX1. **b** Indel rates estimated by T7E1 assay by spCas9 and miCas9 with or without the use of RAD51 inhibitor, B02. **c** Co-IP results by using anti-flag (left) or anti-RAD51 (right) antibodies followed western blot for RAD51 or Cas9. **d** ChIP assay results with anti-RAD51 antibody at the proximal region of the sg-AAVS1 target locus. Sp: spCas9, Mi: miCas9, Mi-mut: miCas9-mutant. #Reads: Average amplicon reads per sample. Three independent experiments were performed for each condition. Data are presented as mean ± standard error of means (SEM). Unpaired t-test (two tailed) was used to compare data using GraphPad Prism 8 software (GraphPad Software, Inc, San Diego, CA). Source data are available in the Source Data file.
Human Ad293 cells (Cat# 240085, Agilent, Santa Clara, CA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Cat# 11995-065, ThermoFisher Scientific) with 10% fetal bovine serum. Human CD34+ HSCs (Cat# PCS-800-012, ATCC) were cultured in StemSpan SFEM II medium (Cat# 09655, StemCell Technologies) supplemented with SCF (100 ng/ml), TPO (100 ng/ml), Flt3L (100 ng/ml), IL-6 (100 ng/ml), UM171 (35 nM), 20 μM streptomycin, and penicillin, and SR1 (Stemgent) (0.75 μM).

Human Jurkat cells (Cat# TIB-152, ATCC) were cultured in RPMI-1640 medium (Cat# 30-2001, ATCC) supplemented with 10% FBS.

Cas9s and guide RNAs. Unless otherwise specified in the context, “Cas9” in the “Methods” section refers to any Cas9 variant (e.g. spCas9, miCas9, miCas9mA, miniHiFiCas9, HypaCas9) that is used in a given experiment. To construct miCas9, dead-spCas9-VP64 (Cat# 47754, Addgene) was reverse engineered to spCas9-VP64 by performing the reverse mutations of A102D and A840H, followed by replacement of VP64 with the Bres27 sequence. The spCas9-expressing plasmid DNA was constructed on the same backbone by removing the Bres27 sequence.

To construct spCas9MsA or miCas9MsA, the mSA coding sequence was amplified from pDisplay-mSA-EGFP-TM (Cat# 39863, Addgene) and inserted to the C-terminus of spCas9 or miCas9 with optimized linkers on both sides. To construct HiFiCas9 and miniHiFiCas9 plasmids, we generated the R691A mutation on the spCas9 and the miCas9 plasmids. HypaCas9 (Cat# 101178), Cas9-HE (Cat# 109400), and Cas9-GE (Cat# 109401) plasmid DNAs were acquired from Addgene (www.addgene.org).

To enable RNP experiments using miCas9, we produced recombinant miCas9 protein from E. coli. The miCas9 DNA sequence with 5′ SV40 nuclear localization signal (NLS) was obtained by PCR-amplification and was subcloned into pET30 in frame with a 5′ His-tag to construct the pET30-miCas9 vector, which was then used to transform BL21 (DE3) competent E. coli (Cat# C600003, ThermoFisher Scientific). MiniCas9 proteins were His-tag purified, followed by removal of endotoxin by High Capacity Endotoxin Removal Resin (Cat# 88271, ThermoFisher Scientific). Purified miniCas9 proteins were stored in 50% glycerol at −20 °C. Cas9-HE and Cas9-GE were similarly in-house produced.

For synthesis of sgRNA-expressing plasmid, annealed DNA oligonucleotide duplexes were ligated into pBluescript SK (Cat# 33188, Addgene). For RNP experiments, sgRNAs were in vitro transcribed by using gRNA synthesis kit (Cat# A29377, ThermoFisher Scientific).

KI donor templates. The GFP-expressing ds-DNA donor templates consist of GFP coding sequences flanked by left and right homologous arms corresponding to target sites (Supplementary Table 1). The single-stranded oligonucleotide donor DNA was commercially synthesized by IDT. 5′-Biotin-modified primers were used for PCR to produce biotinylated GFP-expressing donor templates in the miCas9MsA experiments.

Electroporation. We used a tube electroporation machine (Model#ETC10-1500A LE, Celetrix, Manassas, VA) to deliver Cas9 elements (e.g. Cas9 pDNA or RNP, gRNAs, and donor templates) to cells. 2–3 × 10⁶ cells were resuspended in 120 μl electroporation buffer (Cat#13-0104, Celetrix). To deliver Cas9 in plasmid DNA form, 4.5 μg Cas9-expressing pDNA, 1.5 μg sgRNA-expressing pDNAs, and 4 μg GFP-expressing donor templates were added to the buffer. To deliver Cas9 in RNP form, 10 μg Cas9 pre-mixed with 3.3 μg gRNA were added to the buffer. Four micrograms of GFP-expressing donor templates or 10 μg SO Dunn donor templates were added in KI experiments.

The electroporation conditions were 620 V for 30 ms for iPSCs and Ad293 cells, or 635 V for 30 ms for HSCs. The electroporation conditions were 620 V for 30 ms for iPSCs and Ad293 cells, or 635 V for 30 ms for HSCs.

T7EI assay. T7EI (T7 endonuclease I) assay was conducted as previously described. Briefly, the purified PCR products were denatured and re-annealed and digested with T7EI (M0302L, New England BioLabs, Ipswich, MA) at 68 °C for 4 h. For cloning the co-factors with DNA, cells were incubated with 1% freshly prepared paraformaldehyde at room temperature for 10 min. For RAD51 crossing, cells were treated with 2 μl dNucsinicmydyl glutarate (DSS), ThermoFisher Scientific, #20593) at room temperature for 45 min before 1% paraformaldehyde incubation for 10 min. Then the crossing was quenched by 0.1% glacial acetic acid at room temperature for 5 min. Nuclei were digested with Micrococcal Nuclease at 37 °C for 20 min followed by sonication (Branson Sonifier SLPe, 20 s of 30% amplification, three times). Chromatin was immunoprecipitated with antibodies against RAD51 (Novus Biologicals, NB100-148, 1:50 dilution) or normal mouse IgG (Sigma 12-371, 1:500 dilution) at 4 °C overnight with rotation. ChIP grade Protein G magnetic beads were added to the IP samples and rotated 2 h at 4 °C. DNA was eluted after washing the beads the three times with low-salt wash buffer, one time with high-salt wash buffer, and one time with LiCl buffer. After treatment with Proteinase K at 65 °C for 2 h, the DNA was purified and then amplified by real-time PCR with the following primers and the AAVS1 sgRNA target site: 5′-CGGAAAGGAGGCCCTAAGGA-3′ and 5′-ATTTGAGCCCTGTGTTCCTGGT-3′.

Co-immunoprecipitation. Ad293 cells were transfected with spCas9 or miCas9 as described above. After 72 h, lysed with Pierce IP Lysis Buffer (ThermoScientific, #87788). The cell lysate was sonicated for 3 times, 5 seconds each using a Branson Sonifier SLPe at 35% amplitude and centrifuged at 4 °C, 21,000 g for 10 min. The cell lysate was incubated with anti-FLAG M2 beads (Sigma, M8823) at 4 °C overnight. The immunocomplexes were then eluted for western blot analysis for RAD51 (Novus Biologicals, NB100-148, 1:1000 dilution or Abclonal, A6268, 1:1000 dilution). For the reverse immunoprecipitation, the cell lysate after sonication was pre-cleaned with Protein A Magnetic Beads (CST, #73778) at room temperature for 20 min before incubating with primary antibody for 1 h at 4 °C. The lysate was then analyzed by western blotting at 1:1000 dilution (Abclonal, A6268, 1:1000 dilution) at 4 °C overnight with rotation. The immunocomplexes were then precipitated with Protein A Magnetic Beads and eluted for western blot analysis for Cas9 (Abclonal, A14997, 1:2000 dilution).

Sequence information of guide RNAs, ssODNs, ds-KI donors, and primers. Sequence information of guide RNAs, ssODNs, ds-KI donors, and primers are provided in Supplementary Tables 1–4.

Statistics and reproducibility. Quantitative data are presented as mean ± SEM. Measurements were taken from three distinct samples. Unpaired t-test (two-tailed) was used to compare data using GraphPad Prism 8 software (GraphPad Software, Inc., San Diego, CA). Exact P values are labeled in figures. At least two independent experiments were conducted to confirm the results in Co-IP (Fig. 6c), western blot during library construction. Libraries were pooled in equimolar concentrations for multiplexed sequencing on the Illumina MiSeq platform with 2 × 150 run parameters. Sequencing data were analyzed, demultiplexed, and subsequently entered into an automated de novo pipeline. Analysis was completed through the MGH CCB’s de novo assembler UltraCycler v1.0, manually inspected for quality control. A brief description of the algorithm is available at https://dncore.mgh.harvard.edu/new-cgo-bio-site/pages/crispseq_sequencing_pages/crispseq_algorithm_sp.pdf. PGE and indel rates were determined by the CRISPRezzo tool (https://crispresso.pinellolab.partners.org/) using .fastq files. For analysis of the PGE and indel rates at CCR5-del32, where the primer and ampiclon sequences are highly homologous with those at CCR2, the .seq files were analyzed by Blastx (https://blast.ncbi.nlm.nih.gov) against the HDR ampiclon sequence and the wild-type ampiclon sequence.
References

1. Adli, M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 9, 1911 (2018).
2. Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).
3. Pawelczak, K. S., Gavande, N. S., VanderVere-Carozza, P. S. & Turchi, J. J. Modulating DNA repair pathways to improve precision genome engineering. ACS Chem. Biol. 13, 389–396 (2018).
4. Paquet, D. et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533, 125–129 (2016).
5. Richards, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Turchi, J. J. Modulating DNA repair pathways to improve precision genome engineering. ACS Chem. Biol. 13, 389–396 (2018).
6. Davis, L. & Maizels, N. Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair. Proc. Natl. Acad. Sci. USA 111, E924–E932 (2014).
7. DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).
8. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J. S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012–1019 (2014).
9. DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).
10. Kan, Y., Ruis, B., Takasugi, T. & Hendrickson, E. A. Mechanisms of precise genome editing using oligonucleotide donors. Genome Res. 27, 1099–1111 (2017).
11. Harmsen, T., Klaasen, S., van de Vrugt, H. & Te Riele, H. DNA mismatch repair and oligonucleotide end-protection promote base-pair substitution distal from a CRISPR/Cas9-induced DNA break. Nucleic Acids Res. 46, 2945–2955 (2018).
12. Davis, L. & Maizels, N. Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair. Proc. Natl. Acad. Sci. USA 111, E924–E932 (2014).
13. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas9-mediated gene editing. Cell 153, 910–918 (2013).
14. Yang, H. et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas9-mediated genome engineering. Cell 154, 1370–1379 (2013).
15. Yu, C. et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16, 142–147 (2015).
16. Gutschner, T., Haemmerle, M., Genovese, G., Draetta, G. F. & Chin, L. Posttranslational regulation of Cas9 during G1 enhances homology-directed repair. Cell Rep. 14, 1555–1566 (2016).
17. Charpentier, M. et al. ClpP fusion to Cas9 enhances transgene integration by homology-dependent repair. Nat. Commun. 9, 1133 (2018).
18. Gu, B., Posfai, E. & Rossant, J. Efficient generation of targeted large insertions by microinjection into two-cell-stage mouse embryos. Nat. Biotechnol. 36, 632–637 (2018).
19. Shao, S. et al. Enhancing CRISPR/Cas9-mediated homology-directed repair in mammals by expressing Saccharomyces cerevisiae Rad52. Int. J. Biochem. Cell Biol. 92, 43–52 (2017).
20. Jayavaradhan, R. et al. CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. Nat. Commun. 10, 2866 (2019).
21. Ali, Z. et al. Fusion of the Cas9 endonuclease and the VirD2 relaxase facilitates homology-directed repair for precise genome engineering in rice. Commun. Biol. 3, 44 (2020).
22. Tran, N. T. et al. Enhancement of precise gene editing by the association of Cas9 with homologous recombination factors. Front. Genet. 10, 365 (2019).
23. Howden, S. E. et al. A Cas9 variant for efficient generation of Indel-free knockin or gene-corrected human pluripotent stem cells. Stem Cell Rep. 7, 508–517 (2016).
24. Saymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84–88 (2016).
25. Kleinert, B. P. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490–495 (2016).
26. Hu, J. H. et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 556, 57–63 (2018).
27. Chen, J. S. et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature 550, 407–410 (2017).
28. Yavuzkus, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1726–1728 (2018).
29. Ogawa, T., Yu, X., Shinohara, A. & Egelman, E. H. Similarity of the yeast RAD51 filament to the bacterial RecA filament. Science 259, 1896–1899 (1993).
30. Sung, P. & Robberson, D. L. DNA strand exchange mediated by a RAD51-sDNA nucleoprotein filament with polarity opposite to that of RecA. Cell 82, 453–461 (1995).
31. Jasins, M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 21, 8891–8993 (2002).
32. Davies, O. R. & Pellegrini, L. Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat. Struct. Mol. Biol. 17, 475–483 (2007).
33. He, X. et al. Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res. 44, e85 (2016).
34. Pinder, J., Salams, J. & Dellaire, G. Nuclear domain ‘knock-in’ screen for the evaluation and identification of small molecule enhancers of CRISPR-based gene editing. Nucleic Acid. Res. 43, 9379–9392 (2015).
35. Irion, S. et al. Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat. Biotechnol. 25, 1477–1482 (2007).
36. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013).
37. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187–197 (2015).
38. Almeida, M. J. & Matos, A. Designer nucleases: gene-editing therapies using CRISPR/Cas9 as a tool. Nature 533, 125–129 (2016).
39. Huang, F. et al. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem. Biol. 6, 628–635 (2011).
40. Rees, H. A., Yeh, W. H. & Liu, D. R. Development of hRad51-Cas9 nickase fusions that mediate HDR without double-stranded breaks. Nat. Commun. 10, 2212 (2019).
41. Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020).
42. Carlson-Stevermer, J. et al. Assembly of CRISPR ribonucleoproteins with biotinylated oligonucleotides via an RNA aptamer for precise gene editing. Nat. Commun. 8, 1711 (2017).
43. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015).
44. Xu, X. et al. Efficient homology-directed gene editing by CRISPR/Cas9 in human stem and primary cells using tube electroporation. Sci. Rep. 8, 11649 (2018).
45. Clement, K. et al. CRISPRResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224–226 (2019).
